Royal Bank of Canada
RARE icon

Royal Bank of Canada’s Ultragenyx Pharmaceutical RARE Stock Holding History

Royal Bank of Canada’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-2,800
Closed -$199K – 6742
2016
Q3 		$199K Buy
+2,800
New +$179K ﹤0.01% 4434

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Royal Bank of Canada's RARE Position: Q1 2026 in Review

Royal Bank of Canada reduced its Ultragenyx Pharmaceutical (RARE) stake by 98% in Q1 2026, selling an estimated $3.6M and leaving 3,295 shares worth $69K. The position accounts for ﹤0.01% of the portfolio, ranked #5330.

Royal Bank of Canada first reported a position in RARE in Q1 2015 and has held it in 45 quarters since. The position peaked at $13.9M in Q2 2017. 296 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

  • Royal Bank of Canada held 3,295 shares of Ultragenyx Pharmaceutical worth $69K as of Q1 2026.
  • Royal Bank of Canada sold 159,932 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $3.6M.
  • Ultragenyx Pharmaceutical made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #5330 holding.
  • Royal Bank of Canada first reported a position in Ultragenyx Pharmaceutical in Q1 2015 and has held it in 45 quarters since.
  • Royal Bank of Canada's Ultragenyx Pharmaceutical position peaked at $13.9M in Q2 2017.
  • 296 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.